ZA201704912B - Cytomegalovirus antigens and uses thereof - Google Patents

Cytomegalovirus antigens and uses thereof

Info

Publication number
ZA201704912B
ZA201704912B ZA2017/04912A ZA201704912A ZA201704912B ZA 201704912 B ZA201704912 B ZA 201704912B ZA 2017/04912 A ZA2017/04912 A ZA 2017/04912A ZA 201704912 A ZA201704912 A ZA 201704912A ZA 201704912 B ZA201704912 B ZA 201704912B
Authority
ZA
South Africa
Prior art keywords
cytomegalovirus antigens
cytomegalovirus
antigens
Prior art date
Application number
ZA2017/04912A
Other languages
English (en)
Inventor
Yi Xing
Claudio Ciferri
Andrea Carfi
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of ZA201704912B publication Critical patent/ZA201704912B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/082—Hepadnaviridae, e.g. hepatitis B virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/25—Varicella-zoster virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ZA2017/04912A 2015-01-22 2017-07-19 Cytomegalovirus antigens and uses thereof ZA201704912B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15152221.6A EP3048114A1 (en) 2015-01-22 2015-01-22 Cytomegalovirus antigens and uses thereof
PCT/IB2016/050335 WO2016116904A1 (en) 2015-01-22 2016-01-22 Cytomegalovirus antigens and uses thereof

Publications (1)

Publication Number Publication Date
ZA201704912B true ZA201704912B (en) 2018-12-19

Family

ID=52434568

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2017/04912A ZA201704912B (en) 2015-01-22 2017-07-19 Cytomegalovirus antigens and uses thereof

Country Status (24)

Country Link
US (2) US10167321B2 (enExample)
EP (3) EP3048114A1 (enExample)
JP (1) JP6717836B2 (enExample)
KR (1) KR20170100039A (enExample)
CN (1) CN107531761B (enExample)
AU (2) AU2016210548B2 (enExample)
BE (1) BE1023087B1 (enExample)
BR (1) BR112017015567A2 (enExample)
CA (1) CA2974041C (enExample)
DK (1) DK3247722T5 (enExample)
EA (1) EA038250B1 (enExample)
ES (1) ES2937959T3 (enExample)
FI (1) FI3247722T3 (enExample)
HR (1) HRP20230177T1 (enExample)
HU (1) HUE061175T2 (enExample)
IL (1) IL253366B (enExample)
LT (1) LT3247722T (enExample)
MX (1) MX382518B (enExample)
PL (1) PL3247722T3 (enExample)
PT (1) PT3247722T (enExample)
SG (1) SG11201705740UA (enExample)
SI (1) SI3247722T1 (enExample)
WO (1) WO2016116904A1 (enExample)
ZA (1) ZA201704912B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2772265T3 (en) * 2010-05-14 2018-04-30 Univ Oregon Health & Science Recombinant HCMV and RHCMV vectors and uses thereof
ES2667425T3 (es) 2011-06-10 2018-05-10 Oregon Health & Science University Glucoproteínas y vectores recombinantes de CMV
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
KR102205348B1 (ko) 2014-07-16 2021-01-20 오레곤 헬스 앤드 사이언스 유니버시티 외인성 항원을 포함하는 인간 시토메갈로바이러스
MX2017010027A (es) 2015-02-10 2018-08-15 Univ Oregon Health & Science Métodos y composiciones útiles en la generación de respuestas de células t cd8+ no canónicas.
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
MA42502A (fr) 2015-07-21 2018-05-30 Modernatx Inc Vaccins contre une maladie infectieuse
EP3364950A4 (en) 2015-10-22 2019-10-23 ModernaTX, Inc. VACCINES AGAINST TROPICAL DISEASES
WO2017070613A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Human cytomegalovirus vaccine
CN116926128A (zh) 2015-11-20 2023-10-24 俄勒冈健康与科学大学 包含微小rna识别元件的cmv载体
US11246920B2 (en) 2016-03-03 2022-02-15 Duke University Compositions and methods for inducing HIV-1 antibodies
US11318197B2 (en) 2016-03-03 2022-05-03 Duke University Compositions and methods for inducing HIV-1 antibodies
CA3039089A1 (en) 2016-10-03 2018-04-12 Duke University Methods to identify immunogens by targeting improbable mutations
SG11201903340TA (en) 2016-10-18 2019-05-30 Univ Oregon Health & Science Cytomegalovirus vectors eliciting t cells restricted by major histocompatibility complex e molecules
MA46584A (fr) 2016-10-21 2019-08-28 Modernatx Inc Vaccin contre le cytomégalovirus humain
EP3582790A4 (en) 2017-02-16 2020-11-25 ModernaTX, Inc. VERY POWERFUL IMMUNOGENIC COMPOSITIONS
MX2019012525A (es) * 2017-04-19 2019-12-05 Glaxosmithkline Biologicals Sa Proteinas de citomegalovirus modificadas y complejos estabilizados.
EP3681514A4 (en) 2017-09-14 2021-07-14 ModernaTX, Inc. RNA VACZINE AGAINST ZIKA VIRUS
WO2019070730A1 (en) 2017-10-02 2019-04-11 Duke University MOSAIC ENVELOPES OF HIV-1 TO INDUCE ADCC RESPONSES
US11771755B2 (en) 2018-02-28 2023-10-03 University Of Washington Self-asssembling nanostructure vaccines
EP3773708A2 (en) 2018-04-03 2021-02-17 Sanofi Antigenic epstein barr virus polypeptides
US12138304B2 (en) 2018-10-01 2024-11-12 Duke University HIV-1 envelope stabilizing mutations
WO2020079586A1 (en) 2018-10-17 2020-04-23 Glaxosmithkline Biologicals Sa Modified cytomegalovirus proteins and stabilized complexes
CN109627330A (zh) * 2018-12-18 2019-04-16 马鞍山史记动物健康管理有限公司 一种猪伪狂犬病毒高效价阳性血清制备方法
US12070495B2 (en) 2019-03-15 2024-08-27 Modernatx, Inc. HIV RNA vaccines
US12419949B2 (en) 2019-07-24 2025-09-23 Glaxosmithkline Biologicals Sa Modified human cytomegalovirus proteins
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
EP4469078A1 (en) 2022-01-28 2024-12-04 GlaxoSmithKline Biologicals S.A. Modified human cytomegalovirus proteins
CN118652325B (zh) * 2022-10-21 2025-05-13 珠海泰诺麦博制药股份有限公司 抗人巨细胞病毒抗体及其用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
EP0452484B2 (en) 1989-11-06 2004-07-28 Cell Genesys, Inc. Production of proteins using homologous recombination
WO2007146024A2 (en) 2006-06-07 2007-12-21 The Trustees Of Princeton University Cytomegalovirus surface protein complex for use in vaccines and as a drug target
EP3009449B1 (en) * 2008-07-16 2018-06-06 Institute for Research in Biomedicine Human cytomegalovirus neutralizing antibodies and use thereof
SG178954A1 (en) 2009-09-02 2012-04-27 Novartis Ag Immunogenic compositions including tlr activity modulators
RU2625546C2 (ru) 2010-07-06 2017-07-14 Новартис Аг Катионные эмульсии "масло-в-воде"
KR102266691B1 (ko) 2010-10-11 2021-06-23 노파르티스 아게 항원 전달 플랫폼
RU2649133C2 (ru) 2011-07-06 2018-03-29 Новартис Аг Катионные эмульсии масло-в-воде
TWI570240B (zh) * 2011-09-09 2017-02-11 默沙東公司 作為細胞巨大病毒疫苗之條件式複製ｃｍｖ
IN2014KN02929A (enExample) 2012-07-06 2015-05-08 Novartis Ag
JP6294890B2 (ja) * 2012-10-30 2018-03-14 ファイザー・インク ヒトサイトメガロウイルス感染に対する組換え粒子ベースのワクチン
EP3083676B1 (en) 2013-12-20 2019-08-28 Novartis AG Novel eukaryotic cells and methods for recombinantly expressing a product of interest
WO2015092737A1 (en) 2013-12-20 2015-06-25 Novartis Ag Novel eukaryotic cells and methods for recombinantly expressing a product of interest
EP3015475A1 (en) 2014-10-31 2016-05-04 Novartis AG Mammalian cells expressing cytomegalovirus antigens
EP3047856A1 (en) 2015-01-23 2016-07-27 Novartis AG Cmv antigens and uses thereof

Also Published As

Publication number Publication date
WO2016116904A1 (en) 2016-07-28
MX382518B (es) 2025-03-13
CA2974041A1 (en) 2016-07-28
EP3048114A1 (en) 2016-07-27
EP4180056A1 (en) 2023-05-17
DK3247722T5 (da) 2024-10-07
HRP20230177T1 (hr) 2023-04-14
CA2974041C (en) 2023-04-04
SI3247722T1 (sl) 2023-04-28
EP3247722B1 (en) 2022-11-30
AU2016210548A1 (en) 2017-08-10
JP2018504117A (ja) 2018-02-15
CN107531761A (zh) 2018-01-02
AU2016210548B2 (en) 2018-11-08
PT3247722T (pt) 2023-01-31
US20170369532A1 (en) 2017-12-28
HUE061175T2 (hu) 2023-05-28
US20190276498A1 (en) 2019-09-12
CN107531761B (zh) 2022-01-14
JP6717836B2 (ja) 2020-07-08
BE1023087A1 (fr) 2016-11-18
EP3247722A1 (en) 2017-11-29
LT3247722T (lt) 2023-02-10
PL3247722T3 (pl) 2023-03-20
AU2018226521B2 (en) 2019-10-31
ES2937959T3 (es) 2023-04-03
BR112017015567A2 (pt) 2018-03-13
DK3247722T3 (da) 2023-01-30
AU2018226521A1 (en) 2018-09-27
EA201791562A1 (ru) 2018-04-30
SG11201705740UA (en) 2017-08-30
EA038250B1 (ru) 2021-07-29
BE1023087B1 (fr) 2016-11-18
KR20170100039A (ko) 2017-09-01
US10167321B2 (en) 2019-01-01
FI3247722T3 (fi) 2023-03-17
MX2017009538A (es) 2017-11-02
IL253366B (en) 2022-03-01
IL253366A0 (en) 2017-09-28

Similar Documents

Publication Publication Date Title
IL285375B2 (en) IL-8-binding antibodies and their uses
IL283321A (en) Antibodies against muc16 and their uses
ZA201704912B (en) Cytomegalovirus antigens and uses thereof
IL258284A (en) Anti-Lag 3 antibodies and their uses
IL257263A (en) Antibodies against angptl8 and their use
IL252804B (en) Anti-c10orf54 antibodies and their use
IL251248A0 (en) Anti-interleukin-33 antibodies and their uses
IL254954B (en) Anti-pacap antibodies and their uses
ZA201605894B (en) Anti-egfrviii antibodies and uses thereof
GB201403875D0 (en) Novel antibodies and uses thereof
ZA201701663B (en) Anti-il-25 antibodies and uses thereof
PT3292154T (pt) Anticorpos anti-her3 humano e seus usos
GB201503387D0 (en) Anti-carbapenem antibodies and uses thereof